Breaking News
Sort by:
Top Post
Experimental Cancer Drug May Slow Inflammation Linked to Heart Disease
An experimental drug already tested as a potential treatment for cancer, lung, and Alzheimer’s disease […]
Maternova and MedMira Enter Distribution Agreement to Market Rapid Diagnostics for HIV, Syphilis and Hepatitis
Maternova, accelerating advances in maternal and infant health through innovative, accessible solutions, and MedMira, a […]
Medivir Announces Pia Baumann as Chief Medical Officer (CMO)
Medivir AB, a pharmaceutical company focused on developing innovative treatments for cancer in areas of […]
Celltrion and LISCure Biosciences Announce Strategic Collaboration to Develop Novel Microbiome Treatment for Parkinson's Disease
LISCure Biosciences, a clinical-stage biotech developing advanced microbiome technology with precision targets, announced a multi-year […]
Trodelvy Demonstrates Positive Efficacy Treating Both Platinum-Ineligible and Rapidly Progressing, Post-Platinum Metastatic Urothelial Cancer
Gilead Sciences has announced new and updated positive results from three cohorts of the Phase 2 […]
Takeda Presents Positive Results from Phase 3 Study of Vedolizumab for Prevention of Intestinal Acute Graft-Versus-Host Disease (aGvHD) in Patients Undergoing Allogeneic Hematopoietic Stem Cell Transplantation (allo-HSCT)
Takeda has announced late-breaking data from the Phase 3 GRAPHITE study presented at the 2023 […]
Abivax appoints Dr. Sheldon Sloan, M.D., as Chief Medical Officer
Abivax SA, a Phase 3 clinical-stage biotechnology company focused on developing therapeutics that modulate the […]
Sarepta Therapeutics Announces Initiation of VOYAGENE, a Clinical Study of SRP-9003 for the Treatment of Limb-Girdle Muscular Dystrophy Type 2E/R4
Sarepta Therapeutics, the leader in precision genetic medicine for rare diseases, today announced that the […]
Maze Therapeutics to Present Phase 1 Results from First-in-Human Trial Evaluating MZE001 as a Potential Oral Treatment for Pompe Disease
Maze Therapeutics, a company translating genetic insights into new precision medicines, has announced that the […]
Jasper Therapeutics Announces Positive Follow-up Clinical Data from Investigator-Sponsored Study of Briquilimab Conditioning in Sickle Cell Disease Patients
Jasper Therapeutics, a biotechnology company focused on developing novel antibody therapies targeting c-Kit (CD117) to […]
Global Sarcoma Therapy Now Approved For New Zealand Patients
Independent biopharmaceutical company, Specialised Therapeutics (ST), is pleased to announce that its portfolio therapy to […]
- Eloxx Pharmaceuticals Announces Final Data Assessment from Phase 2 Combination Clinical Trial of ELX-02 in Class 1 Cystic Fibrosis Patients Read more
- Verge Genomics Announces Positive Safety and Tolerability Data from the Phase 1 Clinical Trial of VRG50635, a Potential Best-in-Class Therapeutic for All Forms of ALS Read more
- DEM BioPharma Appoints Wendy Young, Ph.D., to Scientific Advisory Board Read more
- Confo Therapeutics Enters into Research Collaboration for GPCR-Targeting Antibody Discovery with AbCellera Read more
- Vyriad Announces Expansion of T-Cell Lymphoma Trial at Mayo Clinic Read more